Viva Biotech Holdings disclosed in its June 2026 Monthly Return that the company cancelled 25.32 million ordinary shares during the month, reducing its issued share capital by 1.19% to 2.10 billion shares.
The authorised share capital remained unchanged at 4.00 billion ordinary shares with a par value of USD 0.000025 each, representing total authorised capital of USD 0.10 million.
Key share-capital movements: • Repurchases and cancellations: 25.32 million shares were repurchased and immediately cancelled on 12 June 2026 at an average price of HKD 1.387641. • Pending cancellation: A further 11.01 million shares repurchased in June are yet to be cancelled, signalling an additional reduction in the share base once processed. • No change in treasury stock: The company held no treasury shares at month-end.
Equity incentive schemes: • Pre-IPO Share Incentive Scheme – 2.22 million options outstanding; no grants, exercises, cancellations or lapses occurred in June. • Post-IPO Share Option Scheme – 13.70 million options outstanding; no movements during the month. The scheme still permits issuance of up to 124.35 million shares.
Public float: Viva Biotech confirmed compliance with the Hong Kong Exchange’s minimum 25% public float requirement as at 30 June 2026.
Liquidity impact: No new shares were issued and no option exercises occurred in June, resulting in zero funds raised from equity issuance.
With continued execution of its buyback programme and no new share issuance, Viva Biotech’s share count has moderated, potentially enhancing earnings per share once repurchased shares awaiting cancellation are formally retired.
Comments